Advertisement
Organisation › Details
Akamis Bio Ltd.
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. To achieve that mission, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis Bio has a growing pipeline of T-SIGn® therapeutics anchored by its two clinical-stage programs, NG-350A (an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody) and NG-641 (a stromal-targeted tumor gene therapy leveraging a viral vector encoding a FAP-CD3 bispecific antibody, CXCL-9, CXCL-10 & interferon alpha). NG-350A and NG-641 are both being investigated in ongoing Phase 1 clinical studies in patients with metastatic or advanced epithelial tumors. In addition to internal pipeline development efforts, Akamis Bio has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI). *
Start | 2023-01-05 renamed | |
Group | Akamis Bio (Group) | |
Predecessor | PsiOxus Therapeutics Ltd. | |
Industry | oncolytic virus (cancer-cilling virus, virotherapy for cancer, virus-based cancer therapy) | |
Person | Davis, Howard E. (PsiOxus 202208– CEO based in Boston area before Atlas Venture + Third Harmonic Bio + Flagship) | |
Person 2 | Paoletti, Paolo (GammaDelta Therapeutics 201705– CEO before Kesios Therapeutics CEO + GSK) | |
Region | Abingdon, Oxfordshire | |
Country | United Kingdom (GB) | |
Street | Barton Lane Abingdon Science Park, The Quadrant, 4-10 | |
City | OX14 3YS Abingdon, Oxfordshire | |
Tel | +44-1235-835328 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Akamis Bio Ltd.. (1/5/23). "Press Release: Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics". Cambridge, MA & Oxford. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Akamis Bio (Group)
- [1] Akamis Bio Ltd.. (1/5/23). "Press Release: Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics". Cambridge, MA & Oxford....
- [2] PsiOxus Therapeutics Ltd.. (8/11/22). "Press Release: PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer". Oxford....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top